Dr. Reddy’s Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Sep 11, 2019--
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).
“We are pleased to be among the first generics to launch this product,” explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment.”
The EMEND® for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health*.
Dr. Reddy’s Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.
EMEND® is a trademark of Merck Sharp & Dohme Corp.
*IQVIA Retail and Non-Retail MAT July 2019
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosiimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190911005394/en/
CONTACT: INVESTOR RELATIONS
(PH: +91-40- 49002121)
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Dr. Reddy’s Laboratories
Copyright Business Wire 2019.
PUB: 09/11/2019 07:18 AM/DISC: 09/11/2019 07:18 AM